On MArch 14, 2018 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported that its Chief Executive Officer, Philip Serlin, will present a company update at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 8:35 a.m. (EDT) (Press release, BioLineRx, MAR 14, 2018, View Source;p=RssLanding&cat=news&id=2337989 [SID1234524754]). The conference will be held at the Westin Grand Central Hotel in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on BioLineRx’s website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

On March 14, 2018 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, reported the company will present a poster at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois (Press release, Alpine Immune Sciences, MAR 14, 2018, View Source [SID1234524752]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, entitled "CD80 vIgD-Fc proteins combine checkpoint antagonism and costimulatory signaling for potent antitumor immunity," will highlight preclinical data evaluating a novel immuno-oncology molecule derived from the company’s vIgD platform. An abstract of the presentation will be available on AACR (Free AACR Whitepaper) website after March 14, 2018.

Presentation details are as follows:

Session Category:
Clinical Research

Session Title:

Immune Checkpoints 4

Session Date and Time:
Tuesday, April 17, 2018 – 1:00 PM – 5:00 PM

Location:
McCormick Place South, Exhibit Hall A, Poster Section 25

Poster Board Number:
5

A copy of the poster will be made available on the Company’s website after it is presented.

On March 14, 2018 Spherix Incorporated (SPEX), a technology development company committed to the fostering of innovation and monetization of intellectual property, reported a proposed registered public offering of its common stock (Press release, Spherix, MAR 14, 2018, View Source [SID1234538991]). The offering is being made on a "best efforts" basis and subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Laidlaw & Company (UK) Ltd. is acting as exclusive placement agent for the offering.

Spherix intends to use the net proceeds from the offering, if completed, for working capital and general corporate purposes.

The shares are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-222488), that was previously filed with the Securities and Exchange Commission (SEC) and declared effective on January 19, 2018. The shares may be offered only by means of a prospectus supplement and the accompanying base prospectus. The preliminary prospectus supplement and accompanying base prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source and may also be obtained from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 546 Fifth Avenue, 5th Floor, New York, New York 10036, telephone (212) 953-4900, email: [email protected].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Intellia Therapeutics has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Intellia Therapeutics, 2018, MAR 14, 2018, View Source [SID1234524760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 14, 2018 Aduro Biotech, Inc. (NASDAQ:ADRO) reported that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 28th Annual Oppenheimer Healthcare Conference in New York, NY on Wednesday, March 21, 2018, at 9:10 am Eastern Time (Press release, Aduro Biotech, MAR 14, 2018, View Source;p=RssLanding&cat=news&id=2338086 [SID1234524766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro’s website at www.aduro.com.